跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
在 國立陽明交通大學研發優勢分析平台 搜尋內容
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
醫學系婦產學科
醫學院
醫學系
概覽
指紋
網路
人員
(2)
研究成果
(202)
指紋
查看啟用 醫學系婦產學科 的研究主題。這些主題標籤來自此機構會員的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
95% Confidence Interval
32%
Action Potential Duration
17%
Adenomyosis
25%
Advanced Stage
14%
Adverse Events
15%
Angiogenesis
19%
Arrhythmogenesis
51%
ATP Production
15%
Atrial Arrhythmogenesis
20%
Atrial Fibrillation
23%
Atrial Myocytes
13%
Atrial Remodeling
14%
Bipolar Coagulation
18%
C-Myc
12%
Ca2+
25%
Calcium Dysregulation
12%
Calcium Homeostasis
49%
Cardiac Fibroblasts
15%
Cardiac Injury
13%
Cardiac Remodeling
12%
Cardiomyocytes
19%
Cervical Cancer
16%
Chronic Kidney Disease
16%
Cisplatin
20%
Cisplatin-based Chemotherapy
12%
Conventional Laparoscopic
13%
COVID-19
14%
Cyclooxygenase-2
15%
Cyclooxygenase-2 Expression
12%
Electrical Activity
19%
Endometrial Cancer
26%
Endometrial Cancer Staging
12%
Endometrioma Recurrence
12%
Endometriosis
51%
Epithelial Ovarian Cancer
32%
Estrogen
23%
Estrogen Receptor
12%
Fallopian Tube
13%
Fallopian Tube Carcinoma
18%
Fibroblasts
19%
Fibrogenesis
28%
Gonadotropin-releasing Hormone
16%
Gynecologic Oncology Group
12%
Gynecological Laparoscopic Surgery
12%
Heart Failure
18%
Hepatoprotective
12%
Human Atrial Fibroblasts
21%
Human Cardiomyocytes
12%
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
12%
Induced Pluripotent Stem Cells (iPSCs)
30%
Laparoscopic Morcellation
12%
Laparoscopic Myomectomy
22%
Laparoscopic Ovarian Drilling
12%
Laparoscopic Surgery
21%
Laparoscopy
13%
Laparotomy
12%
Levonorgestrel-releasing Intrauterine System (LNG-IUS)
14%
Liver Injury
12%
Mini
12%
Mitochondrial Function
12%
Mouse Model
14%
Myoma
13%
Myomectomy
25%
Na +
13%
Obstetrics
23%
Odds Ratio
16%
Operative Time
17%
Ovarian Cancer
19%
Overall Survival
22%
Oxidative Stress
13%
Parasitic Myoma
12%
Postmenopausal Women
23%
PRISMA
12%
Profibrotic
20%
Pulmonary Vein
43%
Randomized Controlled Trial
16%
Rare Case Report
18%
Recurrence Rate
13%
Retrospective Cohort Study
35%
Right Ventricular Outflow Tract
34%
Round Spermatid Injection
12%
Secondary Cytoreductive Surgery
12%
Single Port
12%
Sinoatrial Node
12%
Sodium
14%
Spike Protein
18%
Staging System
12%
Stress Urinary Incontinence
13%
Taiwan
55%
Taiwanese
26%
Transobturator
12%
Transplantation
12%
Ultraminilaparotomy
12%
Upper Abdominal Pain
12%
Uterine Sarcoma
24%
Uterine Vessels
18%
Vascular Endothelial Growth Factor
19%
Ventricular Arrhythmia
18%
Ventricular Tachycardia
14%
Western Blotting
14%
Medicine and Dentistry
Adenocarcinoma
18%
Adenomyosis
14%
Adverse Event
16%
Angiogenesis
12%
Arrhythmogenesis
32%
Assisted Reproductive Technology
9%
Atrial Fibrillation
12%
Bleeding
18%
Blood Flow
13%
Calcium Homeostasis
18%
Calcium Ion
22%
Cancer
21%
Carbon Dioxide
9%
Carcinoma
14%
Carcinosarcoma
12%
Cardiac Muscle Cell
10%
Case-Control Study
8%
Cervical Cancer
27%
Cervix
10%
Cesarean Section
9%
Chemotherapy
19%
Cisplatin
24%
Clear Cell
10%
Clear Cell Carcinoma
19%
Connective Tissue Cancer
9%
COVID-19
12%
Cyclooxygenase 2
12%
Cystectomy
25%
Cytoreductive Surgery
20%
Dentigerous Cyst
16%
Dienogest
10%
Disease Free Survival
14%
Diseases
22%
Doppler Flowmetry
17%
Doppler Ultrasound
17%
Echography
11%
Endometriosis
32%
Endometrium Carcinoma
12%
Estrogen
8%
Fallopian Tube
9%
Fibroblast
18%
First Trimester Pregnancy
16%
Gestational Age
26%
Gonadorelin Agonist
13%
Gut
12%
Gynecological Oncology
12%
Gynecology
23%
Hysterectomy
8%
Ifosfamide
10%
Immunohistochemistry
12%
Krukenberg Tumor
49%
Laparoscopic Surgery
25%
Laparotomy
12%
Lymph Node Metastasis
9%
Lymphadenopathy
8%
Maintenance Therapy
8%
Menorrhagia
17%
Metastatic Carcinoma
11%
Morcellation
18%
Myoma
41%
Neoplasm
26%
Nitric Oxide
12%
Observational Study
8%
Obstetrics
17%
Odds Ratio
10%
Ovarian Cancer
19%
Ovarian Tumor
9%
Overall Survival
37%
Oxaliplatin
12%
Paclitaxel
11%
Pelvis
19%
Platinum
17%
Polycystic Ovary Syndrome
12%
Postoperative Pain
8%
Premenopause
9%
Prognostic Factor
17%
Progression Free Survival
18%
Proportional Hazards Model
9%
Pulmonary Vein
12%
Pulsatility Index
10%
Randomized Controlled Trial
15%
Recurrence Risk
16%
Recurrent Disease
47%
Recurrent Ovarian Cancer
12%
Retrospective Cohort Study
45%
Retrospective Study
11%
Salpingooophorectomy
8%
Squamous Cell Carcinoma
13%
Stress Incontinence
24%
Systematic Review
43%
Tumor
10%
Uterine Cancer
46%
Uterine Fibroid
20%
Uterine Myomectomy
41%
Uterine Tube Carcinoma
18%
Uterus Sarcoma
24%
Vaginal Hysterectomy
8%
Ventricular Outflow Tract
12%
Visual Analog Scale
8%
Wart Virus
8%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Liver Failure
6%
Adenomyoma
6%
Adenomyosis
24%
Adenosine Phosphate
7%
Adenosine Triphosphate
11%
Antidiabetic Agent
6%
Arrhythmogenesis
100%
Atrial Fibrillation
41%
Bruton Tyrosine Kinase Inhibitor
6%
Butyrate
6%
Calcium Calmodulin Dependent Protein Kinase II
9%
Calcium Ion
61%
Carcinoma
8%
Chemotherapy Regimens
13%
Chronic Kidney Failure
14%
Cisplatin
12%
Collagen Type 1
8%
Comorbidity
6%
Congestive Heart Failure
20%
Cyclooxygenase 2
15%
Cytokine
10%
Decoy Receptor 3
6%
Diabetes Mellitus
15%
Diethylstilbestrol
6%
Diseases
11%
Dysbiosis
6%
Dysmenorrhea
8%
Empagliflozin
12%
Endometriosis
39%
Endometrium Cancer
6%
Endometrium Tumor
12%
Estrogen
17%
Estrogen Receptor
6%
Fibrosis
18%
Fulminant Hepatic Failure
7%
Galectin 3
6%
Gonadorelin Agonist
9%
Heart Atrium Arrhythmia
10%
Heart Atrium Remodeling
7%
Heart Injury
6%
Heart Ventricle Arrhythmia
23%
Heart Ventricle Remodeling
19%
Heart Ventricle Tachycardia
21%
Histone Deacetylase
6%
Ibrutinib
6%
Immunoglobulin Enhancer Binding Protein
8%
Indican
6%
Inflammation
11%
Isoprenaline
11%
Isotopes of Potassium
6%
Lecithinase
10%
Leporidae
27%
Levonorgestrel
14%
Long QT Syndrome
8%
Macrophage Migration Inhibition Factor
6%
Malignant Neoplasm
8%
Menorrhagia
6%
Monocrotaline-Induced Pulmonary Hypertension
6%
Mouse Model
6%
Myocardial Disease
7%
Myocarditis
8%
N [2 [[N [3 (4 Chlorophenyl) 2 Propenyl] N Methylamino]methyl]phenyl] N (2 Hydroxyethyl) 4 Methoxybenzenesulfonamide
6%
Nitric Oxide
12%
Ovary Cancer
6%
Ovary Carcinoma
17%
Overall Survival
8%
Oxide
7%
Paclitaxel
12%
Pathogenesis
9%
Pericarditis
6%
Peritoneum Cancer
6%
Phosphotransferase
9%
Platinum
8%
Potassium
6%
Procollagen
8%
Protein Kinase B
12%
Protein Kinases
7%
Rabbit Model
6%
Raloxifene
6%
Rat
35%
Reactive Oxygen Metabolite
12%
Receptor
17%
Receptor Protein
7%
Recurrent Disease
23%
Short Chain Fatty Acid
7%
Side Effect
7%
Sodium
28%
Sodium Ion
16%
Sodium Proton Exchange Protein
6%
Streptozotocin
6%
Stress Incontinence
12%
Therapeutic Effect
6%
Transcription Factor RUNX2
6%
Transdermal
6%
Trimethylamine
7%
Uterine Cervix Cancer
7%
Vasculotropin
18%
Vasculotropin Receptor 1
6%
Western Blot
23%
Wound Healing
12%